RGC
Regencell Bioscience Holdings Limited
Drug Manufacturers - Specialty & Generic
Market Cap$14.48B
5Y Perf.+12034.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RGC vs ATHA
Revenue, margins, valuation, and 5-year total return — side by side.
ATHA
Athira Pharma, Inc.
Biotechnology
Market Cap$17M
5Y Perf.-95.1%
RGC vs ATHA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RGC | ATHA |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $14.48B | $17M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-5M | $-129M |
| Total Debt | $86K | $803K |
| Cash & Equiv. | $3M | $69M |
RGC vs ATHA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RGC
ATHA
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Regencell Bioscienc… (RGC) | 100 | 12134.3 | +12034.3% |
| Athira Pharma, Inc. (ATHA) | 100 | 4.9 | -95.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RGC vs ATHA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RGC leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
RGC
Regencell Bioscience Holdings Limited
The Income Pick
RGC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.37
- Rev growth 100.0%, EPS growth 26.9%
- 111.3% 10Y total return vs ATHA's -97.5%
Best for: income & stability and growth exposure
ATHA
Athira Pharma, Inc.
The Specific-Use Pick
In this particular matchup, ATHA is outpaced on most metrics by others in the set.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RGC | 100.0% revenue growth vs ATHA's -64.6% |
| Stability / Safety | RGC | Beta 1.37 vs ATHA's 1.38, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RGC | +424.7% vs ATHA's +62.5% |
| Efficiency (ROA) | RGC | -60.2% ROA vs ATHA's -225.7% |
RGC vs ATHA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRGCLAGGINGATHA
ATHAAthira Pharma, Inc.
0leads
RGCRegencell Bioscience …
2leads
6 Total Categories
CATEGORYLEADERvs ATHAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RGC6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
RGC6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
RGC and ATHA operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | RGCRegencell Bioscie… | ATHAAthira Pharma, In… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$4M | -$110M |
| Net IncomeAfter-tax profit | -$5M | -$129M |
| Free Cash FlowCash after capex | -$7M | -$52M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +24.8% |
Insufficient data to determine a leader in this category.
Valuation Metrics
Evenly matched — RGC and ATHA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | RGCRegencell Bioscie… | ATHAAthira Pharma, In… |
|---|---|---|
| Market CapShares × price | $14.5B | $17M |
| Enterprise ValueMkt cap + debt − cash | $14.5B | -$30M |
| Trailing P/EPrice ÷ TTM EPS | -3365.52x | -0.17x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1761.63x | 0.37x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — RGC and ATHA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
RGC leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
RGC delivers a -67.0% return on equity — every $100 of shareholder capital generates $-67 in annual profit, vs $-4 for ATHA. RGC carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATHA's 0.03x. On the Piotroski fundamental quality scale (0–9), RGC scores 4/9 vs ATHA's 2/9, reflecting mixed financial health.
| Metric | RGCRegencell Bioscie… | ATHAAthira Pharma, In… |
|---|---|---|
| ROE (TTM)Return on equity | -67.0% | -3.8% |
| ROA (TTM)Return on assets | -60.2% | -2.3% |
| ROICReturn on invested capital | -43.8% | — |
| ROCEReturn on capital employed | -46.8% | -2.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.01x | 0.03x |
| Net DebtTotal debt minus cash | -$3M | -$68M |
| Cash & Equiv.Liquid assets | $3M | $69M |
| Total DebtShort + long-term debt | $85,741 | $803,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
RGC leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
RGC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RGC five years ago would be worth $1,059,717 today (with dividends reinvested), compared to $234 for ATHA. Over the past 12 months, RGC leads with a +424.7% total return vs ATHA's +62.5%. The 3-year compound annual growth rate (CAGR) favors RGC at 2.5% vs ATHA's -46.7% — a key indicator of consistent wealth creation.
| Metric | RGCRegencell Bioscie… | ATHAAthira Pharma, In… |
|---|---|---|
| YTD ReturnYear-to-date | +42.6% | -37.6% |
| 1-Year ReturnPast 12 months | +424.7% | +62.5% |
| 3-Year ReturnCumulative with dividends | +4204.0% | -84.8% |
| 5-Year ReturnCumulative with dividends | +10497.2% | -97.7% |
| 10-Year ReturnCumulative with dividends | +11134.2% | -97.5% |
| CAGR (3Y)Annualised 3-year return | +2.5% | -46.7% |
RGC leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RGC and ATHA each lead in 1 of 2 comparable metrics.
Risk & Volatility
RGC is the less volatile stock with a 1.37 beta — it tends to amplify market swings less than ATHA's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATHA currently trades 51.9% from its 52-week high vs RGC's 35.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RGCRegencell Bioscie… | ATHAAthira Pharma, In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.37x | 1.38x |
| 52-Week HighHighest price in past year | $83.60 | $8.36 |
| 52-Week LowLowest price in past year | $5.30 | $2.34 |
| % of 52W HighCurrent price vs 52-week peak | +35.0% | +51.9% |
| RSI (14)Momentum oscillator 0–100 | 59.6 | 38.4 |
| Avg Volume (50D)Average daily shares traded | 140K | 46K |
Evenly matched — RGC and ATHA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | RGCRegencell Bioscie… | ATHAAthira Pharma, In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | 4 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RGC leads in 2 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 2 categories are tied.
Best OverallRegencell Bioscience Holdin… (RGC)Leads 2 of 6 categories
Loading custom metrics...
RGC vs ATHA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RGC or ATHA a better buy right now?
Analysts rate Regencell Bioscience Holdings Limited (RGC) a "Hold" — based on 4 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RGC or ATHA?
Over the past 5 years, Regencell Bioscience Holdings Limited (RGC) delivered a total return of +105.
0%, compared to -97. 7% for Athira Pharma, Inc. (ATHA). Over 10 years, the gap is even starker: RGC returned +111. 3% versus ATHA's -97. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RGC or ATHA?
By beta (market sensitivity over 5 years), Regencell Bioscience Holdings Limited (RGC) is the lower-risk stock at 1.
37β versus Athira Pharma, Inc. 's 1. 38β — meaning ATHA is approximately 1% more volatile than RGC relative to the S&P 500. On balance sheet safety, Regencell Bioscience Holdings Limited (RGC) carries a lower debt/equity ratio of 1% versus 3% for Athira Pharma, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — RGC or ATHA?
On earnings-per-share growth, the picture is similar: Regencell Bioscience Holdings Limited grew EPS 26.
9% year-over-year, compared to 2. 0% for Athira Pharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RGC or ATHA?
Regencell Bioscience Holdings Limited (RGC) is the more profitable company, earning 0.
0% net margin versus 0. 0% for Athira Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RGC leads at 0. 0% versus 0. 0% for ATHA. At the gross margin level — before operating expenses — RGC leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RGC or ATHA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RGC or ATHA better for a retirement portfolio?
For long-horizon retirement investors, Regencell Bioscience Holdings Limited (RGC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+111.
3% 10Y return). Both have compounded well over 10 years (RGC: +111. 3%, ATHA: -97. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RGC and ATHA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.